Search - tctmd.com

Displaying 861 - 880 of 1154

Sort: Relevancy | Date

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for November 2016

Shelley Wood

November 30, 2016

News Conference News AHA 2016

My Takeaways From AHA 2016: Too Late, Too Soon—Time Waits for No Trial

Shelley Wood

November 28, 2016

News Conference News AHA 2016

AHA 2016: Back to the Bayou for Functional Tests, NSAIDs, and Intermediate-Risk TAVR

Shelley Wood

November 09, 2016

News Industry News

Positive Five-Year Clinical Data from Micell Technologies’ MiStent Presented at TCT 2016

November 03, 2016

News Industry News TCT 2016

Imaging Study Shows Rate of Strut Coverage and Low Rates of Neouatherosclerosis with Thin Strut Bioresorbable Polymer-Based and Durable Polymer-Based Drug-Eluting Stents

November 02, 2016

News Industry News TCT 2016

Hybrid Sirolimus-Eluting Stents with Biodegradable Polymer Did Not Improve Angiographic Outcomes Compared to Everolimus-Eluting Stents with Durable Polymer in Treatment of Chronic Total Occlusions

November 02, 2016

Presentation TCT 2016

Case Conclusion: How Did We Treat Our Patient?

Presenter: George D. Dangas, Fabio Felice Tarantino, Massimo Fineschi

November 01, 2016

Presentation TCT 2016

Think Twice: BRS First

Presenter: George D. Dangas, Fabio Felice Tarantino, Francesco Saia

November 01, 2016

Presentation TCT 2016

Choose a Drug-Eluting Stent: Heres Why

Presenter: George D. Dangas, Fabio Felice Tarantino, Carlo Cernetti

November 01, 2016

Presentation TCT 2016

Case Introduction: What Device(s) to Choose in a Patient With NSTE-ACS?

Presenter: George D. Dangas, Fabio Felice Tarantino, Massimo Fineschi

November 01, 2016

Presentation TCT 2016

Case Conclusion: How Did We Treat Our Patient?

Presenter: Roxana Mehran, Ferdinando Varbella, Alberto Menozzi

November 01, 2016

Presentation TCT 2016

Intravenous P2Y12 Receptor Inhibitors Transitioning to a Potent Oral Anti-platelet Agent if PCI Is Performed Is Optimal Treatment in NSTE-ACS

Presenter: Roxana Mehran, Ferdinando Varbella, Dominick J. Angiolillo

November 01, 2016

Presentation TCT 2016

To Pretreat or Not to Pretreat? The DUBIUS Trial

Presenter: Roxana Mehran, Ferdinando Varbella, Giuseppe Tarantini

November 01, 2016

Presentation TCT 2016

Case Introduction: An Elderly Patient With NSTE-ACS

Presenter: Roxana Mehran, Ferdinando Varbella, Alberto Menozzi

November 01, 2016

News Industry News TCT 2016

Study Finds No Long-Term Clinical Benefit to Routine Follow-Up Coronary Angiography After PCI

November 01, 2016

Presentation TCT 2016

Opening Salvo: Despite EXCEL And NOBLE, I Don't Believe PCI Should Be the Standard Revascularization Strategy for Most Patients With Left Main CAD!

Presenter: Sanjay Kaul, Jeffrey J. Popma, John D. Puskas

November 01, 2016

Presentation TCT 2016

Return Fire: The Contrarian View - Bioresorbable Scaffolds Provide Meaningful Value for Most Patients Undergoing PCI!

Presenter: Sanjay Kaul, Jeffrey J. Popma, Michael Haude

November 01, 2016

News Conference News TCT 2016

ReACT: Routine Angiographic Follow-up After PCI Does Not Lower Clinical Events

Michael O'Riordan

November 01, 2016

Presentation TCT 2016

Opening Salvo: I Don't Believe Bioresorbable Scaffolds Provide Meaningful Value for Most Patients Undergoing PCI!

Presenter: Sanjay Kaul, Jeffrey J. Popma, Salvatore Cassese

November 01, 2016

Presentation TCT 2016

Opening Salvo: I Don't Believe That Door-to-Balloon Time Is a Critical Metric for Primary PCI In 2016!

Presenter: David J. Cohen, Ajay J. Kirtane, Alan C. Yeung, Hitinder S. Gurm

November 01, 2016

Advertisement

TCTMD’s Top 10 Most Popular Stories for November 2016

My Takeaways From AHA 2016: Too Late, Too Soon—Time Waits for No Trial

AHA 2016: Back to the Bayou for Functional Tests, NSAIDs, and Intermediate-Risk TAVR

Positive Five-Year Clinical Data from Micell Technologies’ MiStent Presented at TCT 2016

Imaging Study Shows Rate of Strut Coverage and Low Rates of Neouatherosclerosis with Thin Strut Bioresorbable Polymer-Based and Durable Polymer-Based Drug-Eluting Stents

Hybrid Sirolimus-Eluting Stents with Biodegradable Polymer Did Not Improve Angiographic Outcomes Compared to Everolimus-Eluting Stents with Durable Polymer in Treatment of Chronic Total Occlusions

Case Conclusion: How Did We Treat Our Patient?

Think Twice: BRS First

Choose a Drug-Eluting Stent: Heres Why

Case Introduction: What Device(s) to Choose in a Patient With NSTE-ACS?

Case Conclusion: How Did We Treat Our Patient?

Intravenous P2Y12 Receptor Inhibitors Transitioning to a Potent Oral Anti-platelet Agent if PCI Is Performed Is Optimal Treatment in NSTE-ACS

To Pretreat or Not to Pretreat? The DUBIUS Trial

Case Introduction: An Elderly Patient With NSTE-ACS

Study Finds No Long-Term Clinical Benefit to Routine Follow-Up Coronary Angiography After PCI

Opening Salvo: Despite EXCEL And NOBLE, I Don't Believe PCI Should Be the Standard Revascularization Strategy for Most Patients With Left Main CAD!

Return Fire: The Contrarian View - Bioresorbable Scaffolds Provide Meaningful Value for Most Patients Undergoing PCI!

ReACT: Routine Angiographic Follow-up After PCI Does Not Lower Clinical Events

Opening Salvo: I Don't Believe Bioresorbable Scaffolds Provide Meaningful Value for Most Patients Undergoing PCI!

Opening Salvo: I Don't Believe That Door-to-Balloon Time Is a Critical Metric for Primary PCI In 2016!

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content